Luis Antonio Díaz

Dr. Luis Antonio Díaz

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2023 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
LDLuis Antonio Díaz
Luis Antonio Díaz
JAJuan Pablo Arab
Juan Pablo Arab
ALAlexandre Louvet
Alexandre Louvet
RBRamón Bataller
Ramón Bataller
MAMarco Arrese
Marco Arrese

27 November 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
JAJuan Pablo Arab
Juan Pablo Arab
LDLuis Antonio Díaz
Luis Antonio Díaz
JRJürgen Rehm
Jürgen Rehm
GIGene Im
Gene Im
MAMarco Arrese
Marco Arrese
PMPhilippe Mathurin
Philippe Mathurin

21 November 2023 in Journal of Hepatology
Verified
Journal Article
Open access
LDLuis Antonio Díaz
Luis Antonio Díaz
EFEduardo Fuentes-Lopez
Eduardo Fuentes-Lopez
FIFrancisco Idalsoaga
Francisco Idalsoaga
GAGustavo Ayares
Gustavo Ayares
OCOscar Corsi
Oscar Corsi
JAJuan Pablo Arab
Juan Pablo Arab
The long-term impact of alcohol-related public health policies (PHPs) on disease burden is unclear. We aimed to assess the association between alcohol-related PHPs and alcohol-related health consequences. We conducted an ecological multi-national study including 169 countries. We collected data on alcohol-related PHPs from the WHO Global Information System of Alcohol and Health 2010. Data on alcohol-related health consequences between 2010-2019 were obtained from the Global Burden of Disease database. We classified PHPs into five items, including criteria for low, moderate, and strong PHP establishment. We estimated an alcohol preparedness index (API) using multiple correspondence analysis (0 lowest and 100 highest establishment). We estimated an incidence rate ratio (IRR) for outcomes according to API using adjusted multilevel generalized linear models with a Poisson family distribution. The median API in the 169 countries was 54 [IQR 34.9-76.8]. The API was inversely associated with alcohol use disorder (AUD) prevalence (IRR 0.13; 95% CI 0.03-0.60; p = 0.010), alcohol-associated liver disease (ALD) mortality (IRR 0.14; 95% CI 0.03-0.79; p = 0.025), mortality due to neoplasms (IRR 0.09; 95% CI 0.02-0.40; p = 0.002), alcohol-attributable hepatocellular carcinoma (HCC) (IRR 0.13; 95% CI 0.02-0.65; p = 0.014), and cardiovascular diseases (IRR 0.09; 95% CI 0.02-0.41; p = 0.002). The highest associations were observed in the Americas, Africa, and Europe. These associations became stronger over time, and AUD prevalence was significantly lower after 2 years, while ALD mortality and alcohol-attributable HCC incidence decreased after 4 and 8 years from baseline API assessment, respectively (p <0.05). The API is a valuable instrument to quantify the robustness of alcohol-related PHP establishment. Lower AUD prevalence and lower mortality related to ALD, neoplasms, alcohol-attributable HCC, and cardiovascular diseases were observed in countries with a higher API. Our results encourage the development and strengthening of alcohol-related policies worldwide. We first developed an alcohol preparedness index, an instrument to assess the existence of alcohol-related public policies for each country. We then evaluated the long-term association of the country's alcohol preparedness index in 2010 with the burden of chronic liver disease, hepatocellular carcinoma, other neoplasms, and cardiovascular disease. The strengthening of alcohol-related public health policies could impact long-term mortality rates from cardiovascular disease, neoplasms, and liver disease. These conditions are the main contributors to the global burden of disease related to alcohol use. Over time, this association has not only persisted but also grown stronger. Our results expand the preliminary evidence regarding the importance of public health policies in controlling alcohol-related health consequences.

1 April 2025 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
PDPojsakorn Danpanichkul
Pojsakorn Danpanichkul
LDLuis Antonio Díaz
Luis Antonio Díaz
KSKanokphong Suparan
Kanokphong Suparan
PTPrimrose Tothanarungroj
Primrose Tothanarungroj
SSSupapitch Sirimangklanurak
Supapitch Sirimangklanurak
JAJuan Pablo Arab
Juan Pablo Arab
Background/Aims: Alcohol represents a leading burden of disease worldwide, including alcohol use disorder (AUD) and alcohol-related liver disease (ALD). We aim to assess the global burden of AUD, ALD, and alcohol-attributable primary liver cancer between 2000–2021.Methods: We registered the global and regional trends of AUD, ALD, and alcohol-related liver cancer using data from the Global Burden of Disease 2021 Study, the largest and most up-to-date global epidemiology database. We estimated the annual percent change (APC) and its 95% confidence interval (CI) to assess changes in age-standardized rates over time.Results: In 2021, there were 111.12 million cases of AUD, 3.02 million cases of ALD, and 132,030 cases of alcohol-attributable primary liver cancer. Between 2000 and 2021, there was a 14.66% increase in AUD, a 38.68% increase in ALD, and a 94.12% increase in alcohol-attributable primary liver cancer prevalence. While the age-standardized prevalence rate for liver cancer from alcohol increased (APC 0.59%; 95% confidence interval [CI] 0.52 to 0.67%) over these years, it decreased for ALD (APC –0.71%; 95% CI –0.75 to –0.67%) and AUD (APC –0.90%; 95% CI –0.94 to –0.86%). There was significant variation by region, socioeconomic development level, and sex. During the last years (2019–2021), the prevalence, incidence, and death of ALD increased to a greater extent in females.Conclusions: Given the high burden of AUD, ALD, and alcohol-attributable primary liver cancer, urgent measures are needed to prevent them at both global and national levels.

16 June 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
LDLuis Antonio Díaz
Luis Antonio Díaz
FIFrancisco Idalsoaga
Francisco Idalsoaga
EFEduardo Fuentes-Lopez
Eduardo Fuentes-Lopez
AMAndrea Márquez‐Lomas
Andrea Márquez‐Lomas
CRCarolina A. Ramírez
Carolina A. Ramírez
JAJuan Pablo Arab
Juan Pablo Arab

8 April 2024 in Hepatology
Verified
Journal Article
Closed access
PDPojsakorn Danpanichkul
Pojsakorn Danpanichkul
MAMajd B. Aboona
Majd B. Aboona
BSBanthoon Sukphutanan
Banthoon Sukphutanan
SKSiwanart Kongarin
Siwanart Kongarin
KDKwanjit Duangsonk
Kwanjit Duangsonk
KWKarn Wijarnpreecha
Karn Wijarnpreecha
Objective: The worldwide burden of cancer is increasing in younger populations. However, the epidemiology of primary liver cancer remains understudied in young adults compared to other cancer forms. Methods: This study analyzed data from the Global Burden of Disease (GBD) study between 2010 and 2019 to assess the age-standardized incidence, mortality, and disability-adjusted life years (DALYs) associated with primary liver cancer in the young (15–49 y), stratified by region, nation, sociodemographic index, and sex. Results: The study found a global estimate of 78,299 primary liver cancer cases, 60,602 deaths, and 2.90 million DALYs in the young population. The Western Pacific region exhibited the highest burden in 2019, showing the most significant increase compared to other regions between 2010–2019. More than half of countries worldwide have undergone an increase in primary liver cancer incidence rates in young adults. Around 12.51% of deaths due to primary liver cancer occur in young individuals. Throughout the study period, there was a significant decline in primary liver cancer mortality due to most etiologies, except for metabolic dysfunction-associated steatotic liver disease (MASLD)-attributable primary liver cancer (annual percentage change [APC] +0.87%, 95% confidence interval 0.70–1.05%) and alcohol-attributable primary liver cancer (APC +0.21%, 95% confidence interval 0.01–0.42%). Limitations of the GBD database include reliance on the quality of primary data and possible underestimation of alcohol consumption. Conclusion: Over the past decade, there has been a marked increase in the burden of primary liver cancer, especially that originating from steatotic liver disease. This trend calls for the development of urgent and comprehensive strategies to mitigate this rising burden globally. Export